294 related articles for article (PubMed ID: 23657115)
21. G protein-coupled receptor 84 controls osteoclastogenesis through inhibition of NF-κB and MAPK signaling pathways.
Park JW; Yoon HJ; Kang WY; Cho S; Seong SJ; Lee HW; Yoon YR; Kim HJ
J Cell Physiol; 2018 Feb; 233(2):1481-1489. PubMed ID: 28574596
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of receptor activator of nuclear factor-κB ligand- or lipopolysaccharide-induced osteoclast formation by conophylline through downregulation of CREB.
Koide N; Kondo Y; Odkhuu E; Ulziisaikhan J; Ukaji T; Yokochi T; Umezawa K
Immunol Lett; 2014 Sep; 161(1):31-7. PubMed ID: 24792671
[TBL] [Abstract][Full Text] [Related]
23. Tatarinan O, a lignin-like compound from the roots of Acorus tatarinowii Schott inhibits osteoclast differentiation through suppressing the expression of c-Fos and NFATc1.
Xu X; Liu N; Wang Y; Pan LC; Wu D; Peng Q; Zhang M; Wang HB; Sun WC
Int Immunopharmacol; 2016 May; 34():212-219. PubMed ID: 26971224
[TBL] [Abstract][Full Text] [Related]
24. Ginsenoside Rh2 inhibits osteoclastogenesis through down-regulation of NF-κB, NFATc1 and c-Fos.
He L; Lee J; Jang JH; Lee SH; Nan MH; Oh BC; Lee SG; Kim HH; Soung NK; Ahn JS; Kim BY
Bone; 2012 Jun; 50(6):1207-13. PubMed ID: 22484180
[TBL] [Abstract][Full Text] [Related]
25. Angelica sinensis extract inhibits RANKL-mediated osteoclastogenesis by down-regulated the expression of NFATc1 in mouse bone marrow cells.
Kong L; Zhao Q; Wang X; Zhu J; Hao D; Yang C
BMC Complement Altern Med; 2014 Dec; 14():481. PubMed ID: 25496242
[TBL] [Abstract][Full Text] [Related]
26. Inhibitory effects of obovatol on osteoclast differentiation and bone resorption.
Kim HJ; Hong JM; Yoon HJ; Kwon BM; Choi JY; Lee IK; Kim SY
Eur J Pharmacol; 2014 Jan; 723():473-80. PubMed ID: 24334279
[TBL] [Abstract][Full Text] [Related]
27. Ethanol extract of Polyscias fruticosa leaves suppresses RANKL-mediated osteoclastogenesis in vitro and LPS-induced bone loss in vivo.
Tran PT; Dang NH; Kim O; Van Cuong P; Dat NT; Hwangbo C; Van Minh C; Lee JH
Phytomedicine; 2019 Jun; 59():152908. PubMed ID: 30981187
[TBL] [Abstract][Full Text] [Related]
28. Costunolide inhibits osteoclast differentiation by suppressing c-Fos transcriptional activity.
Cheon YH; Song MJ; Kim JY; Kwak SC; Park JH; Lee CH; Kim JJ; Kim JY; Choi MK; Oh J; Kim YC; Yoon KH; Kwak HB; Lee MS
Phytother Res; 2014 Apr; 28(4):586-92. PubMed ID: 23832494
[TBL] [Abstract][Full Text] [Related]
29. Suppression of osteoclastogenesis by N,N-dimethyl-D-erythro-sphingosine: a sphingosine kinase inhibition-independent action.
Kim HJ; Lee Y; Chang EJ; Kim HM; Hong SP; Lee ZH; Ryu J; Kim HH
Mol Pharmacol; 2007 Aug; 72(2):418-28. PubMed ID: 17504945
[TBL] [Abstract][Full Text] [Related]
30. The Coumarin Derivative 5'-Hydroxy Auraptene Suppresses Osteoclast Differentiation via Inhibiting MAPK and c-Fos/NFATc1 Pathways.
Abdallah BM; Ali EM; Elsawy H; Badr GM; Abdel-Moneim AM; Alzahrani AM
Biomed Res Int; 2019; 2019():9395146. PubMed ID: 31976330
[TBL] [Abstract][Full Text] [Related]
31. Calycosin Suppresses RANKL-Mediated Osteoclastogenesis through Inhibition of MAPKs and NF-κB.
Quan GH; Wang H; Cao J; Zhang Y; Wu D; Peng Q; Liu N; Sun WC
Int J Mol Sci; 2015 Dec; 16(12):29496-507. PubMed ID: 26690415
[TBL] [Abstract][Full Text] [Related]
32. Euphorbia factor L1 inhibits osteoclastogenesis by regulating cellular redox status and induces Fas-mediated apoptosis in osteoclast.
Hong SE; Lee J; Seo DH; In Lee H; Ri Park D; Lee GR; Jo YJ; Kim N; Kwon M; Shon H; Kyoung Seo E; Kim HS; Young Lee S; Jeong W
Free Radic Biol Med; 2017 Nov; 112():191-199. PubMed ID: 28774817
[TBL] [Abstract][Full Text] [Related]
33. A novel small molecule, NecroX-7, inhibits osteoclast differentiation by suppressing NF-κB activity and c-Fos expression.
Kim HJ; Yoon KA; Lee MK; Kim SH; Lee IK; Kim SY
Life Sci; 2012 Nov; 91(19-20):928-34. PubMed ID: 23000100
[TBL] [Abstract][Full Text] [Related]
34. Activation of liver X receptor attenuates endothelin-1 expression in vascular endothelial cells.
Gao M; Zeng Y; Guan Y; Hu Z; Zhong D; Shen X; Zhang L; Xu Z; Gong W; Zhang Y; Zhang M; Zheng Y; He F
Int J Biochem Cell Biol; 2012 Dec; 44(12):2299-307. PubMed ID: 23018104
[TBL] [Abstract][Full Text] [Related]
35. Iguratimod (T-614) suppresses RANKL-induced osteoclast differentiation and migration in RAW264.7 cells via NF-κB and MAPK pathways.
Gan K; Yang L; Xu L; Feng X; Zhang Q; Wang F; Tan W; Zhang M
Int Immunopharmacol; 2016 Jun; 35():294-300. PubMed ID: 27085680
[TBL] [Abstract][Full Text] [Related]
36. The tyrosine kinase inhibitor GNF-2 suppresses osteoclast formation and activity.
Kim HJ; Yoon HJ; Choi JY; Lee IK; Kim SY
J Leukoc Biol; 2014 Feb; 95(2):337-45. PubMed ID: 24130113
[TBL] [Abstract][Full Text] [Related]
37. n-3 polyunsaturated fatty acids stimulate osteoclastogenesis through PPARγ-mediated enhancement of c-Fos expression, and suppress osteoclastogenesis through PPARγ-dependent inhibition of NFkB activation.
Nakanishi A; Tsukamoto I
J Nutr Biochem; 2015 Nov; 26(11):1317-27. PubMed ID: 26303404
[TBL] [Abstract][Full Text] [Related]
38. Hispidulin attenuates bone resorption and osteoclastogenesis via the RANKL-induced NF-κB and NFATc1 pathways.
Nepal M; Choi HJ; Choi BY; Yang MS; Chae JI; Li L; Soh Y
Eur J Pharmacol; 2013 Sep; 715(1-3):96-104. PubMed ID: 23791609
[TBL] [Abstract][Full Text] [Related]
39. [Effect of the liver X receptor agonist on LPS-induced inflammatory response associated factor IRAK-4 and NF-kappaB].
Wang D; Miao CM; Gong JP
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2009 Apr; 25(4):293-5, 298. PubMed ID: 19351492
[TBL] [Abstract][Full Text] [Related]
40. Cysteine proteinase inhibitors regulate human and mouse osteoclastogenesis by interfering with RANK signaling.
Strålberg F; Henning P; Gjertsson I; Kindlund B; Souza PP; Persson E; Abrahamson M; Kasprzykowski F; Grubb A; Lerner UH
FASEB J; 2013 Jul; 27(7):2687-701. PubMed ID: 23572233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
